Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jan 2;24(1):2.
doi: 10.1186/s12883-023-03516-9.

The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study

Kourosh Farzin  1 , Azita Kheiltash  2 , Abbas Tafakhori  3 , Nasim Ebadati Nakhjiri  1 , Mahdi Shafiee Sabet  4 , Nahid Dehghan Nayeri  5
Affiliations
Randomized Controlled Trial

The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study

Kourosh Farzin et al. BMC Neurol. .

Abstract

Background: Migraine is a headache disorder that affects public health and reduces the patient's quality of life. Preventive medication is necessary to prevent acute attacks and medication overuse headaches (MOH). Agomelatine is a melatonin antagonist.

Aims: This study aimed to determine the effectiveness of agomelatine on the severity and frequency of migraine attacks.

Methods: The study is a parallel randomized controlled trial with two groups of intervention and control. 400 patients were evaluated. Eligible individuals, including those with episodic migraine headaches without aura between the ages of 18 and 60 years who did not receive preventive treatment beforehand, were enrolled. Also, patients did not receive any specific medications for other diseases. Among these, 100 people met the inclusion criteria and entered the study. These subjects were randomly assigned to one of the two groups. The intervention group received 25 mg of agomelatine daily and the control group received B1. In this study, the effect of agomelatine on the frequency and severity of attacks, mean monthly migraine days (MMD), and migraine disability assessment (MIDAS), were assessed. The study was triple-blind and after three months, a post-test was performed. Data were analyzed using SPSS software.

Results: A total of 100 patients were randomly assigned to either intervention or control groups. The prescriber physician and the data collector did not know about the allocation of patients to groups. Before the intervention, there was no significant difference in the headache frequency per month (t=-0.182, df = 98, p = 0.85), mean MMD (p = 0.17), headache severity (p = 0.076), and MIDAS (p = 0.091). After the study, there was a significant difference between the two groups in terms of the headache frequency per month (p = 0.009), and mean of MMD (p = 0.025). There was also a significant difference between pretest and posttest in two groups in the headache severity (p < 0.001) and MIDAS (p < 0.001).

Conclusion: Agomelatine can be used as a preventive medication for migraine without aura. It is suggested that agomelatine be studied in comparison with other preventive drugs for patients with migraine.

Trial retrospectively registration: Trial Retrospectively registration= IRCT20230303057599N1. Date: 2023-5-24 The present study is a residency thesis approved by the Tehran University of Medical Sciences.

Keywords: Agomelatine; Headache frequency; Headache severity; Migraine.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest to be reported.

Figures

Fig. 1
Fig. 1
CONSORT diagram
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Reviews Neurol. 2023;19(2):109–17. doi: 10.1038/s41582-022-00763-1. - DOI - PubMed
    1. Alatawi AM, Moria HA, Alharfy AAN, Alotaibi JTA, Ali M, Alyami M, Alzahrani AMMM, Albalawi ZSD, Albalawi MB. The prevalence of migraine headache among the general population and its impact on quality of life in Tabuk City, Saudi Arabia. Med Sci. 2023;27:e48ms2692. doi: 10.54905/disssi/v27i131/e48ms2692. - DOI
    1. Ducros A, de Gaalon S, Roos C, Donnet A, Giraud P, Guégan-Massardier E, Lantéri-Minet M, Lucas C, Mawet J, Moisset X. Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: pharmacological treatment. Rev Neurol. 2021;177(7):734–52. doi: 10.1016/j.neurol.2021.07.006. - DOI - PubMed
    1. Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S. Migraine: epidemiology and systems of care. The Lancet. 2021;397(10283):1485–95. doi: 10.1016/S0140-6736(20)32160-7. - DOI - PubMed
    1. Taheri R, Nekuvaght Tak A, Masoudian N. Prevalence of migraine headache in patients with psoriasis vulgaris referred to dermatologists in Semnan, Iran: a crosssectional study. Iran J Dermatology. 2021;24(3):166–71.

Publication types